[1]Sukul D,Marc P,Christian T,et al.Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED Chest Pain Study[J]. Clin Cardiol,2014,37(4):227-232£®
[2]G¨¹nebakmaz O,Celik A,Inanc NT,et al.Copeptin level and copeptin response to percutaneous balloon mitral valvuloplasty in mitral stenosis[J]. Cardiology, 2011,120(4):211-216.
[3]Enh¢‰rning S£¬Wang TJ, Nilsson PM£¬et al£®Plasma Copeptin and the Risk of Diabetes Mellitus[J]. Circulation£¬2010£¬121(19)£º2102-2108£®
[4]Hernandez RD, Garc¢ca SJM, Lopez CA,et al£®High-sensitivity troponin T and copeptin in non-ST acute coronary syndromes: implications for prognosis and role of hsTnT and copeptin in non-STEACS[J]. Sci World J£¬2012£¨2£©:578616. doi: 10.1100/2012/578616.
[5]Mizia SK£¬Lasota B£¬Magdalena M£¬et al. Copeptin constitutes a novel biomarker of degenerative aortic stenosis[J]. Heart Vessels,2013£¬28(5):613-619.
[6]Solymoss BC£¬Bourassa MC£¬Lesperance J£¬et al£®Incidence and characteristics of the metabolic syndrome in patient with coronary artery disease[J]. Coron Artery Dis£¬2003£¬14£º207-212.
[7]Reichlin T£¬Hochholzer W£¬Stelzig C,et al.Incremental value of copeptin for rapid rule out of acute myocardial infarction[J]£®J Am Coll Cardiol£¬2009£¬54(1): 60-68.
[8]Morgenthaler NG.Copeptin:a biomarker of cardiovascular and renal function[J]£®Congest Heart Fail,2010,16(Suppl 1):S37.
[9]Khan SQ£¬Dhillon OS£¬Quinn PA£¬et al£® C-terminal provasopressin (copeptin)as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study[J]. Circulation£¬2007£¬115(16): 2103-2110.
[10]Dieplinger B,Gegenhuber A,Haltmayer M,et al.Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath[J]. Heart,2009,95(18):1508-1513.
[11]Ede H, Kara¢“avu ÿðþ ‰D S,G¢‰¢“men AY£¬et al.Serum copeptin level can be a helpful biomarker in evaluation of myocardial perfusion scintigraphy results[J]. Cardiol J, 2016, 23(1): 71-77.
[12]ÍõÏþÑÞ£¬ÑîÙ©£¬ËïÃ÷£¬µÈ.ÄÔÄÆëļ°ºÍëÄËØˮƽÓë¹ÚÐIJ¡»¼Õß¹ÚÂö²¡±ä³Ì¶ÈµÄÏà¹ØÐÔ[J]. ÖйúÈ«¿ÆҽѧÔÓÖ¾£¬2010£¬13£¨2£©£º145-147.
[13]Morgenthaler NG,Struck J,Jochberger S,et al.Copeptin:clinical use of a new biomarker£ÛJ£Ý.Trends Endocinol Metab,2008,19(2):43-49.
[14]ФÑó£¬ÕÅÖ¾¸Õ£¬²ñÈýÝᣬµÈ£®¶àÖÖ¼²²¡»¼ÕßѪ½¬copeptin²â¶¨[J]£®·ÅÉäÃâÒßѧÔÓÖ¾£¬2008,21(2):97-100.
[15]ÍõÏþÑÞ£¬ÑîÙ©£¬ËïÃ÷£¬µÈ.ÄÔÄÆëÄ¡¢ºÍëÄËغ͸ßÃôC·´Ó¦µ°°×Óë¼±ÐÔ¹ÚÂö×ÛºÏÕ÷µÄÏà¹ØÐÔ[J]. Öйú¶¯ÂöÓ²»¯ÔÓÖ¾£¬2009£¬17£¨2£©£º229-231.
[16]Voors AA£¬von Haehling S£¬Anker SD£¬et al.C-terminal provasopressin£¨copeptin£©is a strong prognosic marker in patients with heart failure after an acute myocardial infarction£ºresults from the OPTIMAAL study[J]. Eur Heart J,2009£¬30£º1187-1194